- Home
- ENSG vs HALO Comparison
ENSG vs HALO Comparison
Compare ENSG & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSG
- HALO
- Stock Information
- Founded
- ENSG 1999
- HALO 1998
- Country
- ENSG United States
- HALO United States
- Employees
- ENSG N/A
- HALO N/A
- Industry
- ENSG Hospital/Nursing Management
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ENSG Health Care
- HALO Health Care
- Exchange
- ENSG Nasdaq
- HALO Nasdaq
- Market Cap
- ENSG 8.9B
- HALO 7.4B
- IPO Year
- ENSG 2007
- HALO N/A
- Fundamental
- Price
- ENSG $144.65
- HALO $57.34
- Analyst Decision
- ENSG Buy
- HALO Buy
- Analyst Count
- ENSG 7
- HALO 9
- Target Price
- ENSG $164.71
- HALO $63.56
- AVG Volume (30 Days)
- ENSG 327.2K
- HALO 2.9M
- Earning Date
- ENSG 07-24-2025
- HALO 08-05-2025
- Dividend Yield
- ENSG 0.17%
- HALO N/A
- EPS Growth
- ENSG 39.72
- HALO 55.40
- EPS
- ENSG 5.30
- HALO 3.76
- Revenue
- ENSG $4,423,354,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- ENSG $17.71
- HALO $25.77
- Revenue Next Year
- ENSG $9.69
- HALO $18.01
- P/E Ratio
- ENSG $27.14
- HALO $15.21
- Revenue Growth
- ENSG 14.81
- HALO 25.64
- 52 Week Low
- ENSG $118.73
- HALO $42.01
- 52 Week High
- ENSG $158.45
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- ENSG 39.34
- HALO 63.54
- Support Level
- ENSG $147.62
- HALO $51.06
- Resistance Level
- ENSG $151.74
- HALO $57.97
- Average True Range (ATR)
- ENSG 2.60
- HALO 1.37
- MACD
- ENSG -1.33
- HALO 0.67
- Stochastic Oscillator
- ENSG 4.74
- HALO 90.88
About ENSG The Ensign Group Inc.
Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.